FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin ...

The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...

Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures. The long, complex process that it takes to successfully bring a drug to market is one of the biggest ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by qualified research institutions, drug developers will not only be able to move ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

Novo is open to considering a direct listing of its shares on the New York Stock Exchange, chief executive officer Mike Doustdar told the Financial Times. The shift to listing shares directly would ...

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand ...

The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong. Pharma ...

Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential. The life sciences industry is navigating a pivotal transition in 2026.